Pfizer Inc. (NYSE:PFE) is navigating widening patent battles over mRNA and lipid‑nanoparticle COVID vaccine technology—from suits in Canada, the EU and expanded U.S. litigation to a BioNTech countersuit—while also pausing Premarin vaginal cream distribution in India amid supply disruptions.
Previous Week Recap
- Pfizer, Moderna BioNTech Patent Disputes: Pfizer (PFE) faces patent lawsuits over mRNA vaccine tech with Moderna; BioNTech earlier filed a February countersuit. Traders: watch legal timelines, potential damages, and stock volatility.
- Pfizer Faces Global Lipid Nanoparticle Suits: Pfizer faces patent infringement suits alleging improper use of lipid nanoparticle tech tied to its COVID-19 vaccine; cases filed in Canada, the EU Unified Patent Court and expanded U.S. litigation.
- Pfizer Pauses Premarin Cream in India: Pfizer paused Premarin vaginal cream distribution in India due to supply issues. The company says it’s working to restore product availability in the Indian market as soon as possible.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.